H Y Meltzer

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
  2. ncbi Clozapine-induced weight gain predicts improvement in psychopathology
    Herbert Y Meltzer
    Department of Psychiatry, Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South 306, Nashville, TN 37215, USA
    Schizophr Res 59:19-27. 2003
  3. ncbi The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia
    H Y Meltzer
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Neuropsychopharmacology 24:278-90. 2001
  4. ncbi Treatment of suicidality in schizophrenia
    H Y Meltzer
    Division of Psychopharmacology, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, 1601 23rd Ave South, Suite 306, Nashville, TN 37212, USA
    Ann N Y Acad Sci 932:44-58; discussion 58-60. 2001
  5. ncbi Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options
    Herbert Y Meltzer
    Psychiatric Hospital of Vanderbilt, 1601 23rd Avenue South, Nashville, TN 37212, USA
    Curr Psychiatry Rep 4:279-83. 2002
  6. ncbi Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27
    Herbert Y Meltzer
    Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Psychopharmacology (Berl) 163:1-3. 2002
  7. ncbi A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia
    Herbert Y Meltzer
    Department of Psychiatry, School of Medicine, Vanderbilt University, Nashville, TN, USA
    Psychiatry Res 177:286-93. 2010
  8. ncbi Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance
    H Y Meltzer
    Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, USA
    Am J Psychiatry 154:475-82. 1997
  9. ncbi The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
    J Ichikawa
    The First Floor Laboratory, Psychopharmacology Division, Department of Psychiatry, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Brain Res 858:252-63. 2000
  10. ncbi Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens
    J Ichikawa
    Department of Psychiatry, Vanderbilt University School of Medicine, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Eur J Pharmacol 351:163-71. 1998

Detail Information

Publications98

  1. ncbi Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
    ..Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients...
  2. ncbi Clozapine-induced weight gain predicts improvement in psychopathology
    Herbert Y Meltzer
    Department of Psychiatry, Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South 306, Nashville, TN 37215, USA
    Schizophr Res 59:19-27. 2003
    ..The purpose of this study was to test the hypothesis that clozapine-induced weight gain is related to antipsychotic efficacy at 6 weeks and 6 months after adjusting for initial body weight and severity of illness...
  3. ncbi The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia
    H Y Meltzer
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Neuropsychopharmacology 24:278-90. 2001
    ..These results provide further evidence of dopaminergic dysfunction in SCH. Furthermore, the APO-stimulated cortisol response may be predictive of subsequent clinical response to antipsychotic drug treatment...
  4. ncbi Treatment of suicidality in schizophrenia
    H Y Meltzer
    Division of Psychopharmacology, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, 1601 23rd Ave South, Suite 306, Nashville, TN 37212, USA
    Ann N Y Acad Sci 932:44-58; discussion 58-60. 2001
    ..Some information about suicidality in the patient sample is reported here...
  5. ncbi Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options
    Herbert Y Meltzer
    Psychiatric Hospital of Vanderbilt, 1601 23rd Avenue South, Nashville, TN 37212, USA
    Curr Psychiatry Rep 4:279-83. 2002
    ..The results support the superiority of clozapine over olanzapine to reduce the risk of suicidality and suggest its use should be considered for all patients with schizophrenia with high risk for suicide...
  6. ncbi Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27
    Herbert Y Meltzer
    Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Psychopharmacology (Berl) 163:1-3. 2002
  7. ncbi A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia
    Herbert Y Meltzer
    Department of Psychiatry, School of Medicine, Vanderbilt University, Nashville, TN, USA
    Psychiatry Res 177:286-93. 2010
    ..These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia...
  8. ncbi Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance
    H Y Meltzer
    Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, USA
    Am J Psychiatry 154:475-82. 1997
    ..The authors compared age at onset in neuroleptic-resistant and -responsive schizophrenic patients to determine whether the gender difference in age at onset is related to response to neuroleptic treatment...
  9. ncbi The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
    J Ichikawa
    The First Floor Laboratory, Psychopharmacology Division, Department of Psychiatry, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Brain Res 858:252-63. 2000
    ..The significance of these results for EPS and antipsychotic action is discussed...
  10. ncbi Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens
    J Ichikawa
    Department of Psychiatry, Vanderbilt University School of Medicine, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Eur J Pharmacol 351:163-71. 1998
    ....
  11. ncbi DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release
    J Ichikawa
    Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Brain Res 907:151-5. 2001
    ..These results suggest that 5-HT2A receptor stimulation increases basal cortical dopamine release via 5-HT1A receptor stimulation, and inhibits clozapine-induced cortical dopamine release by diminishing 5-HT2A receptor blockade...
  12. ncbi Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat
    J F Nash
    Department of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, Ohio
    J Pharmacol Exp Ther 249:236-41. 1989
    ..In light of other evidence that GEP has D2 antagonist effects in vivo, we hypothesize that GEP and perhaps IPS are partial dopamine agonists which may contribute to their antianxiety and/or antidepressant properties...
  13. ncbi RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy
    C M Niswender
    Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA
    Neuropsychopharmacology 24:478-91. 2001
    ..These findings suggest that alterations in RNA editing may contribute to or complicate therapy in certain psychiatric disorders...
  14. ncbi Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs
    M Maes
    Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
    Schizophr Res 21:39-50. 1996
    ..e. CC16, and that the latter may constitute a trait market of schizophrenia; and that (ii) chronic treatment with atypical antipsychotic agents, i.e., risperidone, may normalize lower plasma CC16 and increase plasma sIL-2R...
  15. ncbi 5-HT(1A) receptor dysfunction in female patients with schizophrenia
    M A Lee
    Department of Psychiatry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37212, USA
    Biol Psychiatry 50:758-66. 2001
    ....
  16. ncbi R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum
    J Ichikawa
    Department of Psychiatry, Psychopharmacology Division, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Pharmacol Exp Ther 291:1227-32. 1999
    ..05 mg/kg s.c.), which alone had no effect on DA release. These results suggest that 5-HT(1A) receptor agonism facilitates DA release in mPFC and NAC but not STR in combination with D(2) receptor antagonism...
  17. ncbi Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex
    S Matsubara
    Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106
    Life Sci 45:1397-406. 1989
    ..Dibenzo-epines (clozapine, loxapine, amoxapine, chlothiapine) consistently downregulate 5-HT2 receptors in frontal cortex after acute treatment...
  18. ncbi Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia
    H Y Meltzer
    Department of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Curr Pharm Biotechnol 13:1572-86. 2012
    ....
  19. ncbi The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats
    M Horiguchi
    Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Psychopharmacology (Berl) 221:205-15. 2012
    ..Atypical antipsychotic drugs (APDs), many of which are direct or indirect serotonin (5-HT)(1A) agonists, and tandospirone, a 5-HT(1A) partial agonist, have been reported to improve cognition in schizophrenia...
  20. ncbi The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens
    J Ichikawa
    Department of Psychiatry, Psychopharmacology Division, Vanderbilt University School of Medicine, Nashville, USA
    Brain Res 842:445-51. 1999
    ..The mechanism and clinical significance of these results for developing antipsychotic drugs is discussed...
  21. ncbi Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens
    D L Willins
    Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
    Brain Res 781:291-9. 1998
    ..These results suggest that the activation of 5-HT2C receptors selectively inhibits morphine-induced DA release in the NAc in a manner which is independent of the inhibition of 5-HT neurons...
  22. ncbi Reduced levels of norepinephrine transporters in the locus coeruleus in major depression
    V Klimek
    Department of Psychiatry, University of Mississippi Medical Center, Jackson, Mississippi 39216 4505, USA
    J Neurosci 17:8451-8. 1997
    ....
  23. ncbi The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats
    M Horiguchi
    Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Pharmacol Exp Ther 338:605-14. 2011
    ..These results suggest 5-HT(7) antagonism may contribute to the efficacy of some atypical APDs in the treatment of cognitive impairment in schizophrenia and may itself have some benefit in this regard...
  24. ncbi Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
    J Ichikawa
    Department of Psychiatry, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Eur Arch Psychiatry Clin Neurosci 249:90-8. 1999
    ..The mechanism of action of these drugs is a matter of keen interest. We review here the evidence that some, or all, of these advantages are related to their actions at serotonin and dopamine receptors...
  25. ncbi Melperone in the treatment of neuroleptic-resistant schizophrenia
    H Y Meltzer
    Department of Psychiatry, Psychopharmacology Division, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Psychiatry Res 105:201-9. 2001
    ..The results suggest that a proportion of neuroleptic-resistant patients with schizophrenia respond to melperone, which requires further controlled study...
  26. ncbi Beta-adrenergic receptor binding in frontal cortex of suicide victims
    C A Stockmeier
    Department of Psychiatry, Case Western Reserve University, Cleveland, OH 44106
    Biol Psychiatry 29:183-91. 1991
    ..In these sample groups, suicide by violent means appears to be associated with an increase in the number of serotonin-2, but not beta-adrenergic, receptors in frontal cortex...
  27. ncbi Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist
    S Snigdha
    Division of Psychopharmacology, Vanderbilt Psychiatric Hospital, Nashville TN 37212, USA
    J Pharmacol Exp Ther 332:622-31. 2010
    ....
  28. ncbi Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression
    G A Ordway
    Department of Psychiatry, University of Mississippi Medical Center, Jackson, MS, USA
    Brain Res 847:71-9. 1999
    ..These findings demonstrate that the pathophysiology of major depression is not likely to involve abnormalities in MAO-A...
  29. ncbi Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    H Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn 37212, USA
    J Clin Psychiatry 60:47-51. 1999
    ..Further study of the dose-response curve for loxapine and its usefulness in treating neuroleptic-resistant schizophrenia is indicated...
  30. ncbi Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia
    Tomiki Sumiyoshi
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Psychopharmacology (Berl) 177:79-83. 2004
    ..Cognitive dysfunction in schizophrenia has been demonstrated to be dependent, in part, on dopaminergic activity. Clozapine has been found to improve some domains of cognition, including verbal memory, in patients with schizophrenia...
  31. ncbi Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses
    J F Nash
    Department of Psychiatry and Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106
    Pharmacol Biochem Behav 33:781-5. 1989
    ..These selective changes in receptor responsiveness following the chronic administration of these 5-HT agonists further establishes the independence of 5-HT1A and 5-HT2 receptor-mediated pharmacological effects...
  32. ncbi A novel augmentation strategy for treating resistant major depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Am J Psychiatry 158:131-4. 2001
    ..The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression...
  33. ncbi Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
    T Sumiyoshi
    Department of Neuropsychiatry, Toyama Medical and Pharmaceutical University School of Medicine, Japan
    Am J Psychiatry 158:1722-5. 2001
    ....
  34. ncbi The role of serotonin receptors in the action of atypical antipsychotic drugs
    H Y Meltzer
    Vanderbilt University School of Medicine, Department of Psychiatry, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Curr Opin Pharmacol 11:59-67. 2011
    ..5-HT(2C) receptor antagonism appears to contribute to the weight gain produced by some atypical APDs and may also affect cognition and psychosis via its influence on cortical and limbic dopaminergic activity...
  35. ncbi Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research
    M Maes
    Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio
    Acta Psychiatr Scand 90:252-8. 1994
    ..It is hypothesized that lower esterification in serum cholesterol may constitute a vulnerability factor for depression through alterations in cell membrane microviscosity...
  36. ncbi Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics
    H Y Meltzer
    Department of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn 37212, USA
    J Clin Psychiatry 62:35-9; discussion 40-1. 2001
    ....
  37. ncbi Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor
    L Rauser
    Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, Ohio 44106-4935, USA
    J Pharmacol Exp Ther 299:83-9. 2001
    ....
  38. ncbi 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
    J Ichikawa
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Neurochem 76:1521-31. 2001
    ....
  39. ncbi Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism
    M Horiguchi
    Division of Psychiatry and Behavioural Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USA Dainippon Sumitomo Pharma Co, Ltd, Osaka 564 0053, Japan
    Behav Brain Res 247:158-64. 2013
    ....
  40. ncbi Development of the Clozaril Patient Management System
    B Bastani
    Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106
    Psychopharmacology (Berl) 99:S122-5. 1989
    ..Experience with 31 patients in this outpatient setting suggests that CPMS can be an effective, reliable system for assisting in blood monitoring of patients being treated with clozapine...
  41. ncbi A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects
    Neil D Woodward
    Department of Psychology, Vanderbilt University, 301 Wilson Hall, 111 21st Ave S, Nashville, TN 37203, USA
    Schizophr Res 89:211-24. 2007
    ....
  42. ncbi Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex
    Mei Huang
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University School of Medicine, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Brain Res 1099:44-55. 2006
    ..The clinical significance of this potentiation for the beneficial clinical effects of this combination of agents and the differences between AMS in this regard warrants further study...
  43. ncbi Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response
    Rudi Hwang
    Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
    J Psychopharmacol 21:718-27. 2007
    ..2003), a trend in the same direction was observed as well. Our findings suggest that the rs4532 SNP may have a small effect if any. Further studies in larger, independent samples are required to validate these findings...
  44. ncbi Interpreting the efficacy findings in the CATIE study: what clinicians should know
    Herbert Y Meltzer
    Psychopharmacology Division, Vanderbilt University Medical Center, Nashville, TX 37215, USA
    CNS Spectr 11:14-24. 2006
    ..In particular, the use of a higher-than-usual peak dose of olanzapine may have led to the superior results achieved with it. Practical suggestions are given for choice of antipsychotic medication in patients with chronic schizophrenia...
  45. ncbi Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 31:2033-46. 2006
    ..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity...
  46. ncbi Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
    ....
  47. ncbi Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex
    Mei Huang
    Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Psychopharmacology (Berl) 185:274-81. 2006
    ..The contributions of 5-HT1A receptor stimulation and 5-HT2A and alpha2 adrenergic receptor antagonism to this augmentation are discussed...
  48. ncbi Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia
    Chika Sumiyoshi
    Faculty of Human Development and Culture, Fukushima University, Fukushima, Japan
    Int J Neuropsychopharmacol 9:677-83. 2006
    ..These results suggest a facilitative influence of AAPDs on higher cognitive functions, such as organization of semantic memory, in patients with schizophrenia...
  49. ncbi Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment
    Rudi Hwang
    Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Eur Neuropsychopharmacol 16:248-59. 2006
    ....
  50. ncbi Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach
    Anirban Basu
    Department of Medicine, Section of General Internal Medicine, University of Chicago, 5841 S Maryland Ave, MC 2007, AMD B201, Chicago, IL 60637, USA
    Stat Med 25:2886-910. 2006
    ..In addition, consistent estimation of uncertainty in the time-profile parameters also has important implications for the practice of cost-effectiveness analysis and for future resource allocation policies in schizophrenia treatment...
  51. ncbi COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia
    Neil D Woodward
    Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA
    Schizophr Res 90:86-96. 2007
    ..The results are discussed in relation to previous cross-sectional studies and prospective investigations of the associations between COMT genotype, cognition, and cognitive improvement with atypical APDs in schizophrenia...
  52. ncbi A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition
    Berna Binnur Kivircik Akdede
    Department of Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey
    J Clin Psychiatry 67:1912-9. 2006
    ..The aim of this study was to compare the effect of risperidone or placebo on cognitive function in patients with schizophrenia who were previously treated with clozapine monotherapy...
  53. ncbi SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug
    Andrew C McCreary
    Solvay Pharmaceuticals Research, Weesp, The Netherlands
    Neuropsychopharmacology 32:78-94. 2007
    ..These results suggest that SLV313 is a full 5-HT(1A) receptor agonist and full D(2/3) receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia...
  54. ncbi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  55. ncbi Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt Medical Center, Nashville, TN, USA
    J Clin Psychiatry 69:817-29. 2008
    ..To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily...
  56. ncbi The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux
    Adam J Prus
    Psychology Department, Northern Michigan University, Marquette, MI 49855, USA
    Brain Res 1184:354-64. 2007
    ..0 mg/kg failed to alter the effects of haloperidol (0.1 mg/kg) on DA or ACh efflux in either region. These findings further suggest that NT analogs may be useful alone or adjunctively for the treatment of schizophrenia...
  57. ncbi Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment
    A Carlo Altamura
    Department of Psychiatry, University of Milan, Hospital Luigi Sacco, Via G B Grassi 74, 20157 Milan, Italy
    Int Clin Psychopharmacol 22:249-67. 2007
    ..g. cardiovascular disease)...
  58. ncbi Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study
    Tomiki Sumiyoshi
    Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
    Schizophr Res 95:158-68. 2007
    ..Further study to determine the usefulness of 5-HT1A agonist treatment in schizophrenia is indicated...
  59. ncbi Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 33:1217-28. 2008
    ..A significant and surprisingly large placebo/practice effect was observed among placebo-treated patients, and is a serious consideration in future clinical trial study designs for potential cognitive enhancing compounds in schizophrenia...
  60. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  61. ncbi Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia
    Tomiki Sumiyoshi
    Prog Neuropsychopharmacol Biol Psychiatry 31:965-7. 2007
  62. ncbi Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Proc Natl Acad Sci U S A 104:3019-20. 2007
  63. ncbi Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
    John M Kane
    Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:213-23. 2007
    ..Treatment-resistant schizophrenia poses a major therapeutic challenge. This multicenter, double-blind, randomized study compared the efficacy and safety of aripiprazole and perphenazine in treatment-resistant patients with schizophrenia...
  64. ncbi 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus
    Zhu Li
    Psychopharmacology Division, Psychiatry Department, Vanderbilt University School of Medicine, 1601 23rd Ave South, Suite 306, Nashville, TN 37212, USA
    Brain Res 1134:70-8. 2007
    ..The present data provides additional evidence in support of a possible therapeutic role for 5-HT6 receptor antagonism, as an addition on therapy, to enhance cognitive function in schizophrenia...
  65. ncbi Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol
    Robert M Kessler
    Department of Radiology, Vanderbilt University School of Medicine, University Medical Center, 1161 21st Avenue South, Nashville, TN 37232, USA
    Neuropsychopharmacology 30:2283-9. 2005
    ..Sparing of substantia nigra/VTA dopamine D(2)/D(3) receptor occupancy may contribute to the low incidence of extrapyramidal side effects in olanzapine-treated patients...
  66. ncbi N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors
    Zhu Li
    Psychiatry Department, Psychopharmacology Division, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Neuropsychopharmacology 30:1986-95. 2005
    ....
  67. ncbi Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations
    Rudi Hwang
    Neurogenetics Section, Center for Addiction and Mental Health, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Psychopharmacology (Berl) 181:179-87. 2005
    ..Genetic factors affecting the density and/or function of D(2) receptors may therefore affect AP response...
  68. ncbi Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
    ....
  69. ncbi A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia
    Tomiki Sumiyoshi
    Department of Psychiatry, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Schizophr Res 62:65-72. 2003
    ..The lack of significant side effects such as exacerbation of EPS, pPRL elevation, and weight gain indicates melperone is well tolerated...
  70. ncbi 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
    Toshihide Kuroki
    Department of Neuropsychiatry, Kyushu University Graduate School of Medical Science, Maidashi 3 1 1, Higashiku, Fukuoka 812 8582, Japan
    Brain Res 972:216-21. 2003
    ..Thus, 5-HT(2A) receptor agonism potentiates AMPH-induced DA release in the mPFC and NAC...
  71. ncbi Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, Box 1229, New York, NY 10029, USA
    Psychopharmacology (Berl) 169:404-11. 2003
    ..The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial...
  72. ncbi Atypical antipsychotic drugs improve cognition in schizophrenia
    Herbert Y Meltzer
    Biol Psychiatry 53:265-7; author reply 267-8. 2003
  73. ncbi Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior
    Chan-Hyung Kim
    Department of Psychiatry, Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Schizophr Res 60:71-80. 2003
    ....
  74. ncbi 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain
    Vincenzo S Basile
    Lancet 360:1790-1. 2002
  75. ncbi Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism
    Junji Ichikawa
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Brain Res 956:349-57. 2002
    ..However, 5-HT(1A) agonism may be important only for quetiapine-induced ACh release...
  76. ncbi The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia
    Tomiki Sumiyoshi
    Department of Psychiatry, Division of Psychopharmacology, Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA
    Schizophr Res 59:7-16. 2003
    ..These results suggest the usefulness of melperone for facilitating work and social function in patients with schizophrenia. The differences in the cognition-enhancing abilities between melperone and clozapine are discussed...
  77. ncbi SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
    Stefania Bonaccorso
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Neuropsychopharmacology 27:430-41. 2002
    ..These results suggest that 5-HT(2A/2C) antagonism may be more advantageous than selective 5-HT(2A) antagonism as an adjunct to D(2) antagonists to improve cognition and negative symptoms in schizophrenia...
  78. ncbi 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner
    Jean François Liégeois
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Brain Res 947:157-65. 2002
    ....
  79. ncbi Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment
    Herbert Y Meltzer
    Department of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn 37212, USA
    J Clin Psychiatry 63:25-9. 2002
    ..This article discusses both risks and benefits of antipsychotic treatment and presents a treatment algorithm to aid the clinician in choosing medications for the psychotic patient...
  80. ncbi Regional selectivity in clozapine treatment?
    Robert M Kessler
    Am J Psychiatry 159:1064-5. 2002
  81. ncbi 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex
    Junji Ichikawa
    Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Ther Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Nashville, TN 37212, USA
    Brain Res 939:34-42. 2002
    ..These results suggest that 5-HT(1A) agonism and 5-HT(2A) antagonism, as well as DA release, contribute minimally to the ability of clozapine, and perhaps other atypical APDs, to increase ACh release in the mPFC...
  82. ncbi Reducing the risk for suicide in schizophrenia and affective disorders
    Herbert Y Meltzer
    Division of Psychopharmacology, Psychiatric Hospital, Vanderbilt University Medical Center, Nashville, Tenn, USA
    J Clin Psychiatry 64:1122-9. 2003
  83. ncbi Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms
    Adam J Prus
    Department of Psychology, Virginia Commonwealth University, 808 W. Franklin, Box 842018, Richmond, VA 23284-2018, USA
    Pharmacol Biochem Behav 77:199-208. 2004
    ..25 mg/kg CLZ cue, but only partial substitution for the 5.0 mg/kg CLZ cue. These results provide evidence that antagonism at the muscarinic M(1) receptor is sufficient to provide 1.25 mg/kg CLZ-like discriminative stimulus effects...
  84. ncbi Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia
    Tomiki Sumiyoshi
    Department of Psychiatry, Division of Psychopharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Neuropsychopharmacol 8:451-5. 2005
    ..These results indicate the association of these amino acid measures with response to clozapine in terms of negative symptoms in patients with schizophrenia...
  85. ncbi Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine
    Herbert Y Meltzer
    Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    J Clin Psychiatry 66:530-3. 2005
  86. ncbi A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
    Neil D Woodward
    Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA
    Int J Neuropsychopharmacol 8:457-72. 2005
    ..Atypical antipsychotics produce a mild remediation of cognitive deficits in schizophrenia, and specific atypicals have differential effects within certain cognitive domains...
  87. ncbi Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
    Herbert Y Meltzer
    Vanderbilt University School of Medicine, USA
    Int J Neuropsychopharmacol 8:153-6. 2005
  88. ncbi A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety
    A Elif Anil Yagcioglu
    Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey
    J Clin Psychiatry 66:63-72. 2005
    ....
  89. ncbi The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
  90. ncbi Cognitive factors in schizophrenia: causes, impact, and treatment
    Herbert Y Meltzer
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212 8645, USA
    CNS Spectr 9:15-24. 2004
    ..Verbal learning and executive function, in particular, have been found to be valid predictors of employment success independent of the degree of severity of positive symptoms...
  91. ncbi Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism
    Young-Chul Chung
    Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, 1601 23rd Avenue South, The First Floor Laboratory Rm-1117, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA
    Brain Res 1023:54-63. 2004
    ..The role of hippocampus in the cognitive effects of atypical APDs warrants more intensive study...
  92. ncbi Serotonin 1A receptors in memory function
    Tomiki Sumiyoshi
    Am J Psychiatry 161:1505; author reply 1505-6. 2004
  93. ncbi Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial
    Marc Bourgeois
    Psychopathology Research Laboratory, University of Bordeaux, 3 ter, Place de la Victoire, 33076 Bordeaux, France
    Am J Psychiatry 161:1494-6. 2004
    ..The complex interactions and mediation effects of these clinical variables require careful monitoring...
  94. ncbi Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt University, Nashville, TN, USA
    Am J Psychiatry 161:975-84. 2004
    ....
  95. ncbi A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine
    Tomiki Sumiyoshi
    J Clin Psychopharmacol 24:345-8. 2004
  96. ncbi What's atypical about atypical antipsychotic drugs?
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Avenue South, Nashville, TN 37212, USA
    Curr Opin Pharmacol 4:53-7. 2004
    ..Effects on neuronal survival and plasticity, together with decreased neurotoxicity, might also contribute to their clinical advantage over typical neuroleptic drugs...
  97. ncbi Beyond control of acute exacerbation: enhancing affective and cognitive outcomes
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    CNS Spectr 8:16-8, 22. 2003
    ..Finally, pharmacologic strategies to augment affect and cognitive improvements due to the new antipsychotic drug therapies will be discussed...
  98. ncbi Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
    Junji Ichikawa
    Departments of Psychiatry and Pharmacology, The Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South, Nashville, TN 37212, USA
    Neuropsychopharmacology 26:325-39. 2002
    ..g., early Alzheimer's disease, by enhancing cortical cholinergic transmission...